Ciprofloxacin

Generic Name: Ciprofloxacin

Brand Names: Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈FN_₃O_₃

CAS Number: 85721-33-1

Unique Ingredient Identifier: 5E8K9I0O4U

Background: Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.

The first ciprofloxacin containing product was FDA approved on 22 October 1987.

Indication: Ciprofloxacin is only indicated in infections caused by susceptible bacteria.

Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.

A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa. Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa. A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.

A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis. A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.

A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.

Associated Conditions: Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Clinical Trials

Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

Phase 1

Completed

Conditions: Gonococcal Infection

Interventions: Drug: Azithromycin
Drug: Ceftriaxone
Drug: Ciprofloxacin
Biological: Neisseria gonorrhoeae strain FA1090 A26
Biological: Neisseria gonorrhoeae strain FA7527

First Posted Date: 2021-05-03

Last Posted Date: 2021-12-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT04870138

Locations: 🇺🇸
University of North Carolina Health Care - Infectious Diseases, Chapel Hill, North Carolina, United States

Antibiotic Prophylaxis for Neurogenic Bladder Botox

Phase 2

Recruiting

Conditions: Neurogenic Bladder
Post-operative Urinary Tract Infections

Interventions: Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2021-03-10

Last Posted Date: 2025-02-17

Lead Sponsor: University of Alberta

Target Recruit Count: 160

Registration Number: NCT04791579

Locations: 🇨🇦
University of Alberta, Edmonton, Alberta, Canada

Ciprofloxacin in Drug-resistant Epilepsy

Not Applicable

Completed

Conditions: Epilepsy Intractable

Interventions: Drug: Ciprofloxacin Oral Product

First Posted Date: 2021-02-21

Last Posted Date: 2021-06-07

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 23

Registration Number: NCT04763070

Locations: 🇮🇷
Bu Ali Sina hospital, Sari, Mazandaran, Iran, Islamic Republic of

Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial.

Phase 3

Withdrawn

Conditions: Febrile Neutropenia

Interventions: Drug: Amoxicillin Clavulanate
Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2021-01-06

Last Posted Date: 2022-03-31

Lead Sponsor: Poitiers University Hospital

Registration Number: NCT04698057

CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia)

Not Applicable

Recruiting

Conditions: Acute Lymphoblastic Leukaemia - Category

Interventions: Drug: Ciprofloxacin
Drug: Antibiotic

First Posted Date: 2020-12-22

Last Posted Date: 2024-03-08

Lead Sponsor: University College, London

Target Recruit Count: 1052

Registration Number: NCT04678869

Locations: 🇬🇧
Addenbrookes Hospital, Cambridge, United Kingdom
🇬🇧
Nottingham Children's Hospital, Nottingham, United Kingdom
🇬🇧
Bristol Royal Hospital for Children, Bristol, United Kingdom

and more 11 locations